Video

Is There a Potential Role for Rapcabtagene Autoleucel in R/R LBCL?

Author(s):

Loretta J. Nastoupil, MDMarc S. Hoffman, MD

Experts discuss data on a novel form of CAR T-cell therapy, rapcabtagene autoleucel, for the second-line treatment of R/R LBCL with a faster manufacturing process.

Related Videos
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Sumanta Kumar Pal, MD, FASCO,
Sattva S. Neelapu, MD
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
James Ignatz-Hoover, MD, PhD
Related Content
Here is your guide to important regulatory approvals made by the FDA in May 2024.
May 31st 2024

OncLive’s May Roundup of Key FDA Approvals in Oncology

Matthew Lunning, DO, FACP
December 21st 2023

Lunning and Mehta-Shah Unpack Treatment Needs and Future Directions in PTCL

Benjamin J. Solomon, MBBS, PhD
May 31st 2024

Lorlatinib Yields Longest Reported PFS in Advanced NSCLC

Matthew Lunning, DO, FACP
October 30th 2023

Lunning and Nastoupil Highlight Treatment Considerations and Ongoing Research in Follicular Lymphoma

FDA
May 30th 2024

FDA Approves Liso-Cel for R/R Mantle Cell Lymphoma After 2 Lines of Therapy

Pancreatic Cancer
May 29th 2024

CT041 Shows Tolerability and Early Efficacy in Refractory Metastatic Pancreatic Cancer